Methods for treating B-cell lymphoma by administering an anti-CD20 antibody
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsJoel H. Martin, Li-Hsien Wang, Sean Stevens, Erin M. Allison
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for treating a B-cell lymphoma in a human subject. The methods of the invention comprise administering to a subject in need thereof an antibody or antigen-binding fragment thereof that specifically binds human CD20. In certain embodiments, the methods of the invention are useful for treating non-Hodgkin's B-cell lymphoma.
Claims4
A method for treating a B-cell lymphoma in a human subject, the method comprising administering to the subject a therapeutically effective amount of a human antibody or antigen-binding fragment thereof that specifically binds human CD20, wherein the antibody or antigen-binding fragment thereof comprises:
- (i) a heavy chain complementarity determining region 1 (HCDR1) having the amino acid sequence of SEQ IO NO:341;
- (ii) a heavy chain complementarity determining region 2 (HCDR2) having the amino acid sequence of SEQ ID NO:343;
- (iii) a heavy chain complementarity determining region 3 (HCDR3) having the amino acid sequence of SEQ ID NO:345;
- (iv) a light chain complementarity determining region 1 (LCDR1) having the amino acid sequence of SEQ ID NO:349;
- (v) a light chain complementarity determining region 2 (LCDR2) having the amino acid sequence of SEQ ID NO:351;
- and
- (vi) a light chain complementarity determining region 3 (LCDR3) having the amino acid sequence of SEQ ID NO:353.
Dependencies are inferred from the claim text.